keyword
MENU ▼
Read by QxMD icon Read
search

Mood stabilizing agents

keyword
https://www.readbyqxmd.com/read/27871720/-guidelines-for-the-prescription-of-mood-stabilizers-for-adolescents-a-literature-review
#1
G Munch, N Godart
INTRODUCTION: Adolescence is a unique phase of the human developmental process. In adolescents, psychotropic medications may have different efficacy and tolerance profiles compared to those at other stages of the lifespan. Mood stabilizers are a complex pharmacological category including lithium, some anticonvulsants, and some second generation antipsychotics. Focusing on this class of pharmacological agents, we aim to answer the following questions: in which indications and according to which modalities should mood stabilizers be prescribed during adolescence? METHODS: Information was sought from the websites of the French Haute Autorité de santé (HAS) and Agence nationale de sécurité du médicament et des produits de santé (ANSM), the American Food and Drug Administration (FDA) and the British National Institute for Health and Clinical Excellence (NICE)...
November 18, 2016: L'Encéphale
https://www.readbyqxmd.com/read/27816317/pharmacological-treatment-strategies-in-unipolar-depression-in-european-tertiary-psychiatric-treatment-centers-a-pharmacoepidemiological-cross-sectional-multicenter-study
#2
Markus Dold, Alexander Kautzky, Lucie Bartova, Ulrich Rabl, Daniel Souery, Julien Mendlewicz, Stefano Porcelli, Alessandro Serretti, Joseph Zohar, Stuart Montgomery, Siegfried Kasper
This multicenter, cross-sectional study with retrospective assessment of treatment response evaluated the current prescription trends and pharmacological treatment strategies applied in European university/academic psychiatric centers in unipolar depression. Altogether, 1181 adult in- and outpatients with major depressive disorder (MDD) were enrolled in 9 academic sites in 8 European countries. Socio-demographic, clinical, and medication information were retrieved and the present symptom severity was assessed by the Montgomery and Åsberg Depression Rating Scale (MADRS)...
December 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27737475/pharmacotherapy-in-children-and-adolescents-at-clinical-high-risk-for-psychosis-and-bipolar-disorder
#3
M Lambert, V Niehaus, C Correll
This review aims to describe the importance of i) detecting individuals at clinical high-risk for psychosis (schizophrenia) or bipolar disorder, especially in children and adolescents, in order to enable early intervention, and ii) evaluating different intervention strategies, especially pharmacotherapy, during the subsyndromal or "prodromal" stages of these severe and often debilitating disorders. The different approaches regarding the psychotic and bipolar clinical high-risk state are discussed, including reasons and evidence for early (pharmacological) intervention and risks of treatment vs...
October 13, 2016: Pharmacopsychiatry
https://www.readbyqxmd.com/read/27686028/lamotrigine-compared-to-placebo-and-other-agents-with-antidepressant-activity-in-patients-with-unipolar-and-bipolar-depression-a-comprehensive-meta-analysis-of-efficacy-and-safety-outcomes-in-short-term-trials
#4
Marco Solmi, Nicola Veronese, Leonardo Zaninotto, Marc L M van der Loos, Keming Gao, Ayal Schaffer, Catherine Reis, Claus Normann, Ion-George Anghelescu, Christoph U Correll
OBJECTIVES: To meta-analytically summarize lamotrigine's effectiveness and safety in unipolar and bipolar depression. METHODS: We conducted systematic PubMed and SCOPUS reviews (last search =10/01/2015) of randomized controlled trials comparing lamotrigine to placebo or other agents with antidepressant activity in unipolar or bipolar depression. We performed a random-effects meta-analysis of depression ratings, response, remission, and adverse effects calculating standardized mean difference (SMD) and risk ratio (RR) ±95% confidence intervals (CIs)...
October 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27685435/cognitive-dysfunction-in-major-depression-and-bipolar-disorder-assessment-and-treatment-options
#5
REVIEW
Glenda M MacQueen, Katherine A Memedovich
Cognitive dysfunction is a recognized feature of mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD). Cognitive impairment is associated with poor overall functional outcome and is therefore an important feature of illness to optimize for patients' occupational and academic outcomes. While generally people with BD appear to have a greater degree of cognitive impairment than those with MDD, direct comparisons of both patient groups within a single study are lacking. There are a number of methods for the assessment of cognitive function, but few are currently used in clinical practice...
September 29, 2016: Psychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/27639185/valproic-acid-and-lithium-meditate-anti-inflammatory-effects-by-differentially-modulating-dendritic-cell-differentiation-and-function
#6
Sy-Jye Leu, Yi-Yuan Yang, Hsing-Cheng Liu, Chieh-Yu Cheng, Yu-Chen Wu, Ming-Chyi Huang, Yuen-Lun Lee, Chi-Ching Chen, Winston W Shen, Ko-Jiunn Liu
Valproic acid (VPA), with inhibition activity mainly towards histone deacetylase (HDAC) and Glycogen Synthase Kinase (GSK)-3, and lithium, with inhibition activity mainly toward GSK-3, are both prescribed in clinical as mood-stabilizers and anticonvulsants for the control of bipolar disorder. This study aims to compare the immuno-modulation activities of VPA and lithium, especially on the differentiation and functions of dendritic cells (DC). Our data show that treatment with VPA or lithium effectively alleviated the severity of collagen-induced arthritis triggered by LPS in mice...
September 17, 2016: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/27629159/treatment-recommendations-for-dsm-5-defined-mixed-features
#7
Joshua D Rosenblat, Roger S McIntyre
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) mixed features specifier provides a less restrictive definition of mixed mood states, compared to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), including mood episodes that manifest with subthreshold symptoms of the opposite mood state. A limited number of studies have assessed the efficacy of treatments specifically for DSM-5-defined mixed features in mood disorders. As such, there is currently an inadequate amount of data to appropriately inform evidence-based treatment guidelines of DSM-5 defined mixed features...
September 15, 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27618746/treatment-of-mixed-features-in-bipolar-disorder
#8
Joshua D Rosenblat, Roger S McIntyre
Mood episodes with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)-defined mixed features are highly prevalent in bipolar disorder (BD), affecting ~40% of patients during the course of illness. Mixed states are associated with poorer clinical outcomes, greater treatment resistance, higher rates of comorbidity, more frequent mood episodes, and increased rates of suicide. The objectives of the current review are to identify, summarize, and synthesize studies assessing the efficacy of treatments specifically for BD I and II mood episodes (ie, including manic, hypomanic, and major depressive episodes) with DSM-5-defined mixed features...
September 13, 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27515288/anticonvulsant-medications-attenuate-amphetamine-induced-deficits-in-behavioral-inhibition-but-not-decision-making-under-risk-on-a-rat-gambling-task
#9
Melanie Tremblay, Catharine A Winstanley
Impulsivity is a major component of mania in bipolar disorder (BD), and patients also show impairments in decision-making involving risk on the Iowa Gambling Task (IGT). Similar deficits are observed in some patients with temporal lobe epilepsy (TLE), and incidence of problem gambling is higher in both these populations. Anticonvulsant drugs are widely used in the treatment of epilepsy, but also as mood stabilizers and prophylaxis for the management of BD. Unfortunately, little is still known about the precise mechanisms of action underlying their efficacy, and the specific behavioral aspect targeted by these drugs...
November 1, 2016: Behavioural Brain Research
https://www.readbyqxmd.com/read/27514298/sexual-dysfunction-due-to-psychotropic-medications
#10
REVIEW
Anita H Clayton, Andrew R Alkis, Nishant B Parikh, Jennifer G Votta
Sexual functioning is important to assess in patients with psychiatric illness as both the condition and associated treatment may contribute to sexual dysfunction (SD). Antidepressant medications, mood stabilizers, antipsychotics, and antianxiety agents may be associated with SD related to drug mechanism of action. Sexual adverse effects may be related to genetic risk factors, impact on neurotransmitters and hormones, and psychological elements. Effective strategies to manage medication-induced sexual dysfunction are initial choice of a drug unlikely to cause SD, switching to a different medication, and adding an antidote to reverse SD...
September 2016: Psychiatric Clinics of North America
https://www.readbyqxmd.com/read/27467441/a-systematic-review-on-the-impact-of-psychotropic-drugs-on-electroencephalogram-waveforms-in-psychiatry
#11
Rohit Aiyer, Vladan Novakovic, Robert L Barkin
OBJECTIVES: It is known that psychotropic medications have an impact on the readings found in Electroencephalogram (EEG). In the field of psychiatry, there are several psychotropics utilized by clinicians. This review seeks to investigate all the available data for psychotropic drugs and their impact on EEG changes. METHODS: A systematic review of all the published and ongoing literature was conducted via PubMed. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) method was used for each search...
September 2016: Postgraduate Medicine
https://www.readbyqxmd.com/read/27403245/neuroleptic-malignant-syndrome-associated-with-lithium-toxicity
#12
Vaibhav Patil, Rishab Gupta, Rohit Verma, Yatan Pal Singh Balhara
Neuroleptic Malignant Syndrome (NMS) is an idiosyncratic and potentially life-threatening reaction to neuroleptic drugs. Lithium is a first-line mood stabilizer used in the treatment and prophylaxis of bipolar disorder. There are several case reports of lithium-associated NMS, but only when it was given in combination with antipsychotics. Therefore, the possibility of NMS being secondary to the antipsychotics could not be ruled out in those cases. Here we present a case of lithium-induced NMS in a patient who was not being treated concomitantly with any other agent known to cause NMS...
July 2016: Oman Medical Journal
https://www.readbyqxmd.com/read/27396372/immunoglobulin-a-deficiency-following-treatment-with-lamotrigine
#13
Shinsuke Maruyama, Yasuhiro Okamoto, Mitsuo Toyoshima, Ryosuke Hanaya, Yoshifumi Kawano
Lamotrigine (LTG) is an anti-epileptic drug and mood-stabilizing agent, whose adverse effects include skin rash and dizziness. Interactions with the immune system are rare, and only a few cases linking hypogammaglobulinemia to LTG treatment have been previously described. In this report, we describe a case in which a patient developed hypogammaglobulinemia, and a subsequent immunoglobulin A (IgA) deficiency, following LTG treatment. As a result of her immunodeficiency, the patient presented with a severe urinary tract infection and required intravenous immunoglobulin...
July 7, 2016: Brain & Development
https://www.readbyqxmd.com/read/27346789/endoxifen-a-new-treatment-option-for-mania-a-double-blind-active-controlled-trial-demonstrates-the-antimanic-efficacy-of-endoxifen
#14
A Ahmad, S Sheikh, T Shah, M S Reddy, Bsv Prasad, K K Verma, B B Chandrakant, M Paithankar, P Kale, R V Solanki, R Patel, H Barkate, I Ahmad
The protein kinase C (PKC) signaling system plays a role in mood disorders and PKC inhibitors such as endoxifen may be an innovative medicine for bipolar disorder (BP) patients. In this study we show for the first time the antimanic properties of endoxifen in patients with bipolar I disorder (BPD I) with current manic or mixed episode. In a double-blind, active-controlled study, 84 subjects with BPD I were randomly assigned to receive endoxifen (4 mg/day or 8 mg/day) or divalproex in a 2:1 ratio. Patients orally administered 4 mg/day or 8 mg/day endoxifen showed significant improvement in mania assessed by the Young Mania Rating Scale as early as 4 days...
June 27, 2016: Clinical and Translational Science
https://www.readbyqxmd.com/read/27274384/pharmacotherapy-of-acute-bipolar-depression-in-adults-an-evidence-based-approach
#15
REVIEW
Ather Muneer
In the majority of cases of bipolar disorder, manic episodes are usually brief and typically responsive to currently available psychopharmacological agents. In contrast, depressive manifestations are more prevalent and persistent, and can present as major depressive/mixed episodes or residual interepisode symptoms. The depressive phase is often associated with other neuropsychiatric conditions, such as anxiety spectrum disorders, substance use disorders, stressor-related disorders, and eating disorders. It is viewed as a systemic disease with associated ailments such as metabolic syndrome, diabetes mellitus, and cardiovascular disease...
May 2016: Korean Journal of Family Medicine
https://www.readbyqxmd.com/read/27244871/-antidepressant-resistant-depression-and-the-bipolar-spectrum-diagnostic-and-therapeutic-considerations
#16
REVIEW
Zoltán Rihmer, Xénia Gonda, Annamária Rihmer, Péter Döme
According to the results of epidemiological studies mood disorders with unipolar (major and minor depressive disorder; dysthymia) or bipolar features are among the most prevalent psychiatric disorders. These disorders with their frequent comorbidities (alcohol and/or drug use disorders, smoking, suicide, cardiovascular disorders) pose great public health challenge and cause substantial individual and familar burdens as well. Since SSRIs and other new antidepressant agents entered the market the possibilities to treat depression improved substantially but 25-35 percent of major depressives do not respond even to the second antidepressant trial but the rate of patients who are resistant after the third and fourth adequate antidepressant trial are around only 15-25 and 10 percent, respectively...
2016: Psychiatria Hungarica: A Magyar Pszichiátriai Társaság Tudományos Folyóirata
https://www.readbyqxmd.com/read/27207910/long-acting-injectable-antipsychotics-for-prevention-of-relapse-in-bipolar-disorder-a-systematic-review-and-meta-analyses-of-randomized-controlled-trials
#17
Taro Kishi, Kazuto Oya, Nakao Iwata
BACKGROUND: This meta-analysis of randomized controlled trials aimed to examine the advantages of long-acting injectable antipsychotics over placebo or oral medications regarding efficacy and safety for patients with bipolar disorder. METHODS: Two categorical meta-analyses of randomized controlled trials were performed to compare study-defined relapse rate (primary), discontinuation rates, and individual adverse events: (1) risperidone-long-acting injectable vs placebo, and (2) long-acting injectable antipsychotics vs oral medications...
May 12, 2016: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27190727/the-treatment-of-adult-bipolar-disorder-with-aripiprazole-a-systematic-review
#18
REVIEW
Ather Muneer
Bipolar disorder is characterized by exacerbations of opposite mood polarity, ranging from manic to major depressive episodes. In the current nosological system of the Diagnostic and Statistical Manual - 5(th) edition (DSM-5), it is conceptualized as a spectrum disorder consisting of bipolar disorder type I, bipolar disorder type II, cyclothymic disorder, and bipolar disorder not otherwise specified. Treatment of all phases of this disorder is primarily with mood stabilizers, but many patients either show resistance to the conventional mood stabilizing medications or are intolerant to their side-effects...
2016: Curēus
https://www.readbyqxmd.com/read/27190616/asenapine-augmentation-in-bipolar-disorders-a-case-series
#19
Donatella Marazziti, Federico Mucci, Stefano Baroni, Armando Piccinni
Asenapine, a novel second-generation antipsychotic is effective in acute treatment of bipolar I disorder patients in combination with mood stabilizers even in resistant cases. Although there is no evidence for asenapine's efficacy to be superior to currently available agents, asenapine's favorable weight and metabolic profile are of clinical interest.
May 2016: Clinical Case Reports
https://www.readbyqxmd.com/read/27117589/effect-of-pharmacist-intervention-on-physician-prescribing-in-patients-with-chronic-schizophrenia-a-descriptive-pre-post-study
#20
Yasuhiko Hashimoto, Masami Tensho
BACKGROUND: Although pharmacotherapy is one of the most important treatments for schizophrenia, the prominent levels of antipsychotic polypharmacy and high-dose regimens used in Japan are thought to be inconsistent with treatment regimens used in other countries. In this study, we evaluated the effect of pharmacist intervention on physician prescribing in patients with chronic schizophrenia. METHODS: Participants comprised 52 inpatients at Sawa Hospital (Osaka, Japan), treated with at least one antipsychotic agent, who received pharmacist intervention for 1 year (2012)...
2016: BMC Health Services Research
keyword
keyword
42596
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"